HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lang, A. E. Search for Related Content PubMed Articles by Lang, A. E. Related Collections Parkinson's disease/Parkinsonism Prognosis

The progression of Parkinson disease

A hypothesis

From the Movement Disorders Centre, Toronto Western Hospital, Canada.

Address correspondence and reprint requests to Dr. Anthony E. Lang, Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St., 7 McL, Toronto, ON, Canada, M5T 2S8; e-mail: lang{at}uhnres.utoronto.ca

Recent neuropathologic studies suggest that Parkinson disease (PD) does not begin in the substantia nigra compacta (SNc) but only involves this region later in the course of the disease. It is proposed that once the SNc is affected by the original pathobiological process (for example, protein aggregation), additional processes more specific to dopaminergic neurons are triggered (including sources of oxidative stress such as increased dopamine turnover, reduced levels of reduced glutathione, increased iron, and the presence of neuromelanin, as well as altered calcium homeostasis and excitotoxicity). This results in an acceleration of cell loss in the SNc, causing nigrostriatal degeneration to both reach a threshold for symptoms in advance of earlier affected brain areas and progress more rapidly than other aspects of the disease. Neuroprotective therapy directed solely at more general biologic processes may not have sufficient effects on this accelerated degeneration in the SNc, while neuroprotective therapy designed exclusively to slow the progression of dopaminergic cell loss will not alter the progression of the nondopaminergic symptoms that contribute the greatest disability in the later stages of the disease. Effective disease-modifying therapy may require a cocktail combining treatments designed to address the basic mechanisms of the neurodegeneration and the additional biologic processes specific to the dopaminergic SNc. This hypothesis has implications for the development of disease-modifying therapy and the interpretation of endpoints of clinical trials evaluating the efficacy of such treatments.

Disclosure: The author reports no conflicts of interest.

Received August 11, 2006. Accepted in final form November 6, 2006.

This article has been cited by other articles:

				A. DelleDonne, K. J. Klos, H. Fujishiro, Z. Ahmed, J. E. Parisi, K. A. Josephs, R. Frigerio, M. Burnett, Z. K. Wszolek, R. J. Uitti, et al. Incidental Lewy Body Disease and Preclinical Parkinson Disease Arch Neurol, August 1, 2008; 65(8): 1074 - 1080. [Abstract] [Full Text] [PDF]

				S. Vale Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come? Experimental Biology and Medicine, August 1, 2008; 233(8): 941 - 951. [Abstract] [Full Text] [PDF]

				J Jankovic Parkinson's disease: clinical features and diagnosis J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 368 - 376. [Abstract] [Full Text] [PDF]

				The Parkinson Study Group PRECEPT Investigators Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology, October 9, 2007; 69(15): 1480 - 1490. [Abstract] [Full Text] [PDF]

				W. J. Burke and A. Lang THE PROGRESSION OF PARKINSON DISEASE: A HYPOTHESIS Neurology, August 14, 2007; 69(7): 710 - 711. [Full Text] [PDF]

Correspondence: